Generic entry, price competition, and market segmentation in the prescription drug market

International Journal of Industrial Organization

Volumn 26, Issue 4, 2008, Pages 930-948

  Regan, Tracy L ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

EC2SLS; Generic entry; Market segmentation; One way error component model; Prescription drugs; Price competition

Indexed keywords

COMPETITION; COSTS; DRUG PRODUCTS; MARKETING; MATHEMATICAL MODELS; STRATEGIC PLANNING;

GENERIC ENTRY; MARKET SEGMENTATION; ONE-WAY ERROR COMPONENT MODEL; PRESCRIPTION DRUGS; PRICE COMPETITION;

INDUSTRIAL MANAGEMENT;

EID: 43949098636     PISSN: 01677187     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijindorg.2007.08.004     Document Type: Article

References (40)

1. Baltagi B.H. Simultaneous equations with error components. Journal of Econometrics 17 (1981) 189-200
2. Baltagi B.H. A Hausman test based on the difference between fixed effects two-stage least squares and error components two-stage least squares. Econometric Theory 20 (2004) 223-224
3. Baltagi B.H. A Hausman test based on the difference between fixed effects two-stage least squares and error components two-stage least squares-solution. Econometric Theory 21 (2005) 483-484
4. Baltagi B.H., and Chang Y. Incomplete panels. Journal of Econometrics 62 (1994) 67-89
5. Baltagi B.H., and Chang Y. Simultaneous equations with incomplete panels. Econometric Theory 16 (2000) 269-279
6. Bergman M.A., and Rudholm N. The Relative importance of actual and potential competition: empirical evidence from the pharmaceuticals market. Journal of Industrial Economics 51 (2003) 455-467
7. Berndt E.R. Pharmaceuticals in U.S. Health Care: determinants of quantity and price. Journal of Economic Perspectives 16 (2002) 45-66
8. Berndt, E.R., Kyle, M.K., Ling, D.C., 2003. The long shadow of patent expiration: generic entry and Rx to OTC switches. NBER Conference Volume on Scanner Data and Price Indexes. In: Feenstra, R., Shapiro, M. (Eds.). University of Chicago Press, Chicago, pp. 229-267.
9. Caves R.E., Whinston M.D., and Hurwitz M.A. Patent expiration, entry, and competition in the U.S. Pharmaceutical Industry, Brookings papers. Microeconomics (1991) 1-23
10. Comanor W.S. The political economy of the pharmaceutical industry. Journal of Economic Literature 24 (1986) 1178-1217
11. Cook A. How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry, Congressional Budget Office (1998)
12. Coscelli A. The importance of doctors' and patients' preferences in the prescription decision. Journal of Industrial Economics 48 (2000) 349-369
13. Dean J. Pricing pioneering products. Journal of Industrial Economics 17 (1969) 165-179
14. Ellison G., and Ellison S.F. Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration (2007) Working Paper
15. Ellison S.F., and Mullin W.P. Gradual incorporation of information: pharmaceutical stocks and the evolution of President Clinton's Health Care reform. Journal of Law & Economics 44 (2001) 89-129
16. Ellison S.F., and Snyder C.M. Countervailing Power in Wholesale Pharmaceuticals (2001), Working Paper
17. Ellison S.F., Cockburn I., Griliches Z., and Hausman J. Characteristics of demand for pharmaceutical products: an examination of four cephalosporins. RAND Journal of Economics 28 (1997) 426-446
18. Frank R.G., and Salkever D.S. Pricing patent loss and the market for pharmaceuticals. Southern Economic Journal (1992) 165-179
19. Frank R.G., and Salkever D.S. Generic entry and the pricing of pharmaceuticals. Journal of Economics and Management Strategy 6 (1997) 75-90
20. Grabowski H., and Vernon J. Brand loyalty. Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act, Journal of Law and Economics 35 (1992) 331-350
21. Grabowski H., and Vernon J. Longer patents for increased generic competition in the U.S.-the Waxman-Hatch Act after one decade. PharmacoEconomics 10, 1996 (1996) 110-123
22. Greene W.H. Econometric Analysis. 5th edition (2002), Prentice-Hall, Inc., New Jersey
23. Griliches Z., and Cockburn I. Generics and new goods in pharmaceutical price indexes. American Economic Review 84 (1994) 1213-1232
24. Hellerstein J.K. The importance of the physician in the generic versus trade-name prescription decision. RAND Journal of Economics 29 (1998) 108-136
25. Iizuka T. What explains the use of direct-to-consumer advertising of prescription drugs. Journal of Industrial Economics 52 (2004) 349-379
26. Kamien M.I., and Zang I. Virtual patent extension by cannibalization. Southern Economic Journal 66 (1999) 117-131
27. Kong Y. Prices and Pricing in Imperfectly Competitive Markets, Ph.D. Dissertation (2000)
28. Kong Y., and Seldon J.R. Pseudo-generic products and barriers to entry in pharmaceutical markets. Review of Industrial Organization 25 (2004) 71-86
29. Lu Z.J., and Comanor W.S. Strategic pricing of new pharmaceuticals. Review of Economics and Statistics 80 (1998) 108-118
30. Moulton B.R. Random group effects and the precision of regression estimates. Journal of Econometrics 32 (1986) 385-397
31. Reekie W.D. Price and quality competition in the United States drug industry. Journal of Industrial Economics 26 (1978) 223-237
32. Reiffen D., and Ward M.R. Generic industry dynamics. Review of Economics and Statistics 87 (2005) 37-49
33. Richard O., and Van Horn L. Persistence in prescriptions of branded drugs. International Journal of Industrial Organization 22 (2004) 523-540
34. Saha A., Grabowski H., Birnbaum H., and Greenberg P. Generic Competition in the U.S. Pharmaceutical Industry, [Working Paper] (2003)
35. Scherer F.M. Pricing, profits, and technological progress in the pharmaceutical industry. Journal of Economic Perspectives 7 (1993) 97-115
36. Scott Morton F.M. Entry decisions in the generic pharmaceutical industry. RAND Journal of Economics 30 (1999) 421-440
37. Scott Morton F.M. Barriers to entry. Brand Advertising, and Generic Entry in the US Pharmaceutical Industry, International Journal of Industrial Organization 18 (2000) 1085-1104
38. Stern S. Market Definitions and the Returns to Innovation: Substitution Patterns in Pharmaceutical Markets (1996) Working Paper
39. Suh D., Schondelmeyer S.W., Manning Jr. W.G., Hadsall R.S., and Nyman J.A. Price trends before and after patent expiration in the pharmaceutical industry. Journal of Research in Pharmaceutical Economics 9 (1998) 17-31
40. Wiggins S.N., and Maness R. Price competition in pharmaceuticals. Economic Inquiry 42 (2004) 247-263